Disease · MONDO_0005340
Comparisons in its trials36
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 36
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) vs Main Study: Ritlecitinib 50 mg QD (Roll-over Participants): Main Study: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Until Follow-up Visit | 401 of 447 | 515 of 603 | 1,050 | NCT04006457 | Trial comparisons |
Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) vs Main Study: Ritlecitinib 50 mg QD (Roll-over Participants): Main Study: Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values Until Follow-up Visit | 390 of 444 | 490 of 602 | 1,046 | NCT04006457 | Trial comparisons |
| CTP-543 8 mg BID vs CTP-543 12 mg BID: deaths from any cause | 0 of 367 | 0 of 273 | 640 | NCT05041803 | Trial comparisons |
| CTP-543 8 mg BID vs CTP-543 12 mg BID: Number of Participants With Adverse Events as a Measure of Safety | 308 of 367 | 224 of 273 | 640 | NCT05041803 | Trial comparisons |
| CTP-543 8 mg BID vs CTP-543 12 mg BID: serious adverse events | 16 of 367 | 5 of 273 | 640 | NCT05041803 | Trial comparisons |
| Ruxolitinib Cream vs Placebo Cream: deaths from any cause | 0 of 83 | 0 of 38 | 121 | NCT02553330 | Trial comparisons |
| Ruxolitinib Cream vs Placebo Cream: serious adverse events | 4 of 83 | 0 of 38 | 121 | NCT02553330 | Trial comparisons |
| Part B: Ruxolitinib Cream vs Part B : Placebo Cream: Part B : Percentage of Participants Achieving a SALT50 Response in Terminal Hair (Pigmented and Nonpigmented) | 5 of 39 | 5 of 39 | 78 | NCT02553330 | Trial comparisons |
Part B : Ruxolitinib Cream vs Part B : Placebo Cream: Part B : Percentage of Subjects Whose AA Lesions Treated Since Baseline Achieved a Physician's Global Assessment of Regrowth (PGARG) Score of at Least 3 | 2 of 33 | 5 of 33 | 66 | NCT02553330 | Trial comparisons |
| CTP-543 12 mg BID vs CTP-543 24 mg QD: Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE) | 28 of 34 | 24 of 32 | 66 | NCT03941548 | Trial comparisons |
| CTP-543 12 mg BID vs CTP-543 24 mg QD: deaths from any cause | 0 of 34 | 0 of 32 | 66 | NCT03941548 | Trial comparisons |
| CTP-543 12 mg BID vs CTP-543 24 mg QD: serious adverse events | 0 of 34 | 1 of 32 | 66 | NCT03941548 | Trial comparisons |
| Dupilumab vs Placebo: deaths from any cause | 0 of 40 | 0 of 20 | 60 | NCT03359356 | Trial comparisons |
| Dupilumab vs Placebo: serious adverse events | 1 of 40 | 0 of 20 | 60 | NCT03359356 | Trial comparisons |
| CTP-543 8 mg BID vs CTP-543 16 mg QD: deaths from any cause | 0 of 29 | 0 of 28 | 57 | NCT03811912 | Trial comparisons |
| CTP-543 8 mg BID vs CTP-543 16 mg QD: serious adverse events | 0 of 29 | 0 of 28 | 57 | NCT03811912 | Trial comparisons |
| Alefacept vs Placebo: serious adverse events | 1 of 23 | 2 of 22 | 45 | NCT00167102 | Trial comparisons |
Part B : Ruxolitinib Cream vs Part B : Placebo Cream: Part B : Percentage of Participants With 50% to 100% Scalp Involvement at Baseline Achieving a SALT50 Response in Terminal Hair (Pigmented and Nonpigmented). | 4 of 21 | 2 of 22 | 43 | NCT02553330 | Trial comparisons |
| LEO 124249 vs LEO 124249 Vehicle: deaths from any cause | 0 of 20 | 0 of 11 | 31 | NCT02561585 | Trial comparisons |
| LEO 124249 vs LEO 124249 Vehicle: serious adverse events | 0 of 20 | 0 of 11 | 31 | NCT02561585 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005340/comparisons